KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $67.0 million.

  • Acadia Pharmaceuticals' Share-based Compensation fell 49.63% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year decrease of 33.87%. This contributed to the annual value of $67.0 million for FY2024, which is 0.95% up from last year.
  • Acadia Pharmaceuticals' Share-based Compensation amounted to $67.0 million in FY2024, which was up 0.95% from $66.4 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Share-based Compensation registered a high of $84.4 million during FY2020, and its lowest value of $63.6 million during FY2021.
  • Its 3-year average for Share-based Compensation is $67.2 million, with a median of $67.0 million in 2024.
  • In the last 5 years, Acadia Pharmaceuticals' Share-based Compensation dropped by 24.65% in 2021 and then grew by 7.21% in 2022.
  • Over the past 5 years, Acadia Pharmaceuticals' Share-based Compensation (Yearly) stood at $84.4 million in 2020, then decreased by 24.65% to $63.6 million in 2021, then grew by 7.21% to $68.2 million in 2022, then declined by 2.61% to $66.4 million in 2023, then grew by 0.95% to $67.0 million in 2024.